Department of Pathology, Eulji University School of Medicine, Daejeon, 301-070, Republic of Korea.
Pathol Oncol Res. 2013 Oct;19(4):731-7. doi: 10.1007/s12253-013-9636-y. Epub 2013 May 9.
CTHRC1 has been known as a regulator of collagen expression and cell migration. The aim of this research was to clarify the clinicopathologic significance of CTHRC1 expression in human breast cancer. 22 cases of breast cancer tissues, randomly selected from clinically diagnosed patients, showed a significant increase of CTHRC1 mRNA expression compared to the normal tissue from the same patients using RT-PCR and real-time PCR. Additionally we investigated breast cancers from 189 patients by immunohistochemistry (IHC). A high level of CTHRC1 expression was observed in 111 (58.7 %) out of 189 breast cancer patients and the expression was significantly correlated with histologic grade (P = 0.026), nodal status (P < 0.001), and TNM pathologic stage (P = 0.002). High CTHRC1 expression was associated with a shorter recurrence free survival (P = 0.008). Taken together, the results showed that CTHRC1 over-expression was significantly associated with clinicopathological factors of poor prognosis in invasive ductal carcinoma. CTHRC1 could be used as a supplementary prognostic biomarker and a potential therapeutic target in breast cancer.
CTHRC1 已被证实为胶原蛋白表达和细胞迁移的调控因子。本研究旨在阐明 CTHRC1 在人乳腺癌中的表达与临床病理特征的关系。通过 RT-PCR 和实时 PCR 检测，随机选择的 22 例乳腺癌组织与同患者的正常组织相比，CTHRC1 mRNA 表达显著增加。此外，我们通过免疫组织化学（IHC）检测了 189 例乳腺癌患者的肿瘤。结果发现，189 例乳腺癌患者中有 111 例（58.7%）高表达 CTHRC1，其表达与组织学分级（P=0.026）、淋巴结状态（P<0.001）和 TNM 病理分期（P=0.002）显著相关。高 CTHRC1 表达与无复发生存时间较短显著相关（P=0.008）。综上所述，结果表明 CTHRC1 过表达与浸润性导管癌的临床病理不良预后因素显著相关。CTHRC1 可作为乳腺癌的辅助预后标志物和潜在的治疗靶点。
